Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection — United States, August 2016
Authors: Kate Russell, Sara E. Oliver, Lillianne Lewis, Wanda D. Barfield, Janet Cragan, Dana Meaney-Delman, J. Erin Staples, Marc Fischer, Georgina Peacock, Titilope Oduyebo, Emily E. Petersen, Sherif Zaki, Cynthia A. Moore, Sonja A. Rasmussen, Michael Agus, Donald B. Bailey, Jim Bale, Katherine A. Beckmann, Jatinder Bhatia, Jennifer Bolden Pitre, Timothy J. Brei, Lekisha Daniel-Robinson, Eric Dziuban, Marcus Gaffney, Dixie D. Griffin, Alyson B. Goodman, Manda Hall, R. Phillips Heine, Amy Houtrow, Lisa Hunter, Susan L. Hyman, Wanda K. Jones, Bill G. Kapogiannis, Sharon S. Lehman, Aaron Lopata, Yvonne Maldonado, Edward McCabe, Rima McLeod, Joan Y. Meek, Michael E. Msall, Lynne M. Mofenson, Sitara Nayak, Scott Needle, Susan Reef, Sydney Rice, Scott Rivkees, Jeannie Rodriguez, Elizabeth Rosenblum, Pablo Sanchez, Renate Savich, Angela Scheuerle, Lee Segal, Camille Smith, Parminder S. Suchdev, V. Fan Tait, Edwin Trevathan, Camila V. Ventura, Richard Whitley, Susan Wiley, Fernando Ysern
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

CDC has updated its interim guidance for U.S. health care providers caring for infants born to mothers with possible Zika virus infection during pregnancy (1). Laboratory testing is recommended for 1) infants born to mothers with laboratory evidence of Zika virus infection during pregnancy and 2) infants who have abnormal clinical or neuroimaging findings suggestive of congenital Zika syndrome and a maternal epidemiologic link suggesting possible transmission, regardless of maternal Zika virus test results. Congenital Zika syndrome is a recently recognized pattern of congenital anomalies associated with Zika virus infection during pregnancy that includes microcephaly, intracranial calcifications or other brain anomalies, or eye anomalies, among others (2). Recommended infant laboratory evaluation includes both molecular (real-time reverse transcription-polymerase chain reaction [rRT-PCR]) and serologic (immunoglobulin M [IgM]) testing. Initial samples should be collected directly from the infant in the first 2 days of life, if possible; testing of cord blood is not recommended. A positive infant serum or urine rRT-PCR test result confirms congenital Zika virus infection. Positive Zika virus IgM testing, with a negative rRT-PCR result, indicates probable congenital Zika virus infection. In addition to infant Zika virus testing, initial evaluation of all infants born to mothers with laboratory evidence of Zika virus infection during pregnancy should include a comprehensive physical examination, including a neurologic examination, postnatal head ultrasound, and standard newborn hearing screen. Infants with laboratory evidence of congenital Zika virus infection should have a comprehensive ophthalmologic exam and hearing assessment by auditory brainstem response (ABR) testing before 1 month of age. Recommendations for follow-up of infants with laboratory evidence of congenital Zika virus infection depend on whether abnormalities consistent with congenital Zika syndrome are present. Infants with abnormalities consistent with congenital Zika syndrome should have a coordinated evaluation by multiple specialists within the first month of life; additional evaluations will be needed within the first year of life, including assessments of vision, hearing, feeding, growth, and neurodevelopmental and endocrine function. Families and caregivers will also need ongoing psychosocial support and assistance with coordination of care. Infants with laboratory evidence of congenital Zika virus infection without apparent abnormalities should have ongoing developmental monitoring and screening by the primary care provider; repeat hearing testing is recommended. This guidance will be updated when additional information becomes available.